Literature DB >> 7784080

Expression of beta-galactosidase under the control of the human c-myc promoter in transgenic mice is inhibited by mithramycin.

D E Jones1, D M Cui, D M Miller.   

Abstract

In order to assess the functional contribution of the human c-myc promoter region in the expression of the c-myc gene, transgenic mouse lines containing a bacterial lac Z gene encoding beta-galactosidase under the control of the human c-myc protooncogene promoter were generated. Transgenic mouse embryos heterozygous for the human c-myc Z transgene demonstrate high amounts of beta-galactosidase activity as early as day 11 of embryogenesis by histochemical staining of whole embryos using 5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside (X-Gal) as substrate, localizing specifically to early spinal cord tissue. beta-galactosidase activity can be demonstrated by histochemical staining in brain tissue of day 14 embryos, localizing mainly to the prefrontal cortex region, while relative amounts of beta-galactosidase in spinal cord tissue are reduced. Determination of specific activity of beta-galactosidase using resorufin-beta-galactopyranoside as substrate in homogenates of whole embryos heterozygous for the human c-myc/lac Z transgene demonstrates significantly elevated beta-galactosidase activity over control embryos in day 11 and day 14 embryos. Surprisingly, cell homogenates of brain tissue from adult G1 generation mice heterozygous for the human c-myc/lac Z transgene demonstrate greater than 10-fold higher specific activity of beta-galactosidase over normal control brain tissue. Specific inhibition of the c-myc/lac Z transgene was also demonstrated in developing embryos using mithramycin given at a dose of 150 micrograms kg-1 d-1 intraperitoneal to pregnant females on days 7-13 of gestation. Both histochemical staining of beta-galactosidase and specific activity assays of day 14 embryos demonstrated significantly lower levels of beta-galactosidase than untreated controls. These results are unique since we are able to detect expression of beta-galactosidase in developing embryonic central nervous system tissue along with adult brain tissue of animals carrying the human c-myc Z transgene and we are able to specifically inhibit expression of the transgene using mithramycin administered in utero.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7784080

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  9 in total

1.  ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease.

Authors:  Hoon Ryu; Junghee Lee; Sean W Hagerty; Byoung Yul Soh; Sara E McAlpin; Kerry A Cormier; Karen M Smith; Robert J Ferrante
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-01       Impact factor: 11.205

2.  Ketopremithramycins and ketomithramycins, four new aureolic acid-type compounds obtained upon inactivation of two genes involved in the biosynthesis of the deoxysugar moieties of the antitumor drug mithramycin by Streptomyces argillaceus, reveal novel insights into post-PKS tailoring steps of the mithramycin biosynthetic pathway.

Authors:  Lily L Remsing; Jose Garcia-Bernardo; Ana Gonzalez; Eva Künzel; Uwe Rix; Alfredo F Braña; Daniel W Bearden; Carmen Méndez; Jose A Salas; Jürgen Rohr
Journal:  J Am Chem Soc       Date:  2002-02-27       Impact factor: 15.419

3.  Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease.

Authors:  Robert J Ferrante; Hoon Ryu; James K Kubilus; Santosh D'Mello; Katharine L Sugars; Junghee Lee; Peiyuan Lu; Karen Smith; Susan Browne; M Flint Beal; Bruce S Kristal; Irina G Stavrovskaya; Sandra Hewett; David C Rubinsztein; Brett Langley; Rajiv R Ratan
Journal:  J Neurosci       Date:  2004-11-17       Impact factor: 6.167

4.  Genome-wide modulation of gene transcription in ovarian carcinoma cells by a new mithramycin analogue.

Authors:  Carolina Vizcaíno; Luz-Elena Núñez; Francisco Morís; José Portugal
Journal:  PLoS One       Date:  2014-08-11       Impact factor: 3.240

5.  Large-Scale Drug Screening in Patient-Derived IDHmut Glioma Stem Cells Identifies Several Efficient Drugs among FDA-Approved Antineoplastic Agents.

Authors:  Philip Dao Trong; Gerhard Jungwirth; Tao Yu; Stefan Pusch; Andreas Unterberg; Christel Herold-Mende; Rolf Warta
Journal:  Cells       Date:  2020-06-03       Impact factor: 6.600

Review 6.  SETDB1 in cancer: overexpression and its therapeutic implications.

Authors:  Vanessa J Lazaro-Camp; Kiarash Salari; Xiangbing Meng; Shujie Yang
Journal:  Am J Cancer Res       Date:  2021-05-15       Impact factor: 6.166

7.  Identification of potential therapeutic drugs for huntington's disease using Caenorhabditis elegans.

Authors:  Cindy Voisine; Hemant Varma; Nicola Walker; Emily A Bates; Brent R Stockwell; Anne C Hart
Journal:  PLoS One       Date:  2007-06-06       Impact factor: 3.240

8.  Mithramycin forms a stable dimeric complex by chelating with Fe(II): DNA-interacting characteristics, cellular permeation and cytotoxicity.

Authors:  Ming-Hon Hou; Andrew H-J Wang
Journal:  Nucleic Acids Res       Date:  2005-03-01       Impact factor: 16.971

9.  Gene amplification of the histone methyltransferase SETDB1 contributes to human lung tumorigenesis.

Authors:  M Rodriguez-Paredes; A Martinez de Paz; L Simó-Riudalbas; S Sayols; C Moutinho; S Moran; A Villanueva; M Vázquez-Cedeira; P A Lazo; F Carneiro; C S Moura; J Vieira; M R Teixeira; M Esteller
Journal:  Oncogene       Date:  2013-06-17       Impact factor: 9.867

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.